[Transthoracic intracavernous drug instillation].

C. Virchow,F. Trendelenburg

1965-08-12

Beiträge zur Klinik und Erforschung der Tuberkulose und der Lungenkrankheiten

Abstract:

What problem does this paper attempt to address?

Research needs in allergy: an EAACI position paper, in collaboration with EFA

Nikolaos G Papadopoulos,Ioana Agache,Sevim Bavbek,Beatrice M Bilo,Fulvio Braido,Victoria Cardona,Adnan Custovic,Jan deMonchy,Pascal Demoly,Philippe Eigenmann,Jacques Gayraud,Clive Grattan,Enrico Heffler,Peter W Hellings,Marek Jutel,Edward Knol,Jan Lötvall,Antonella Muraro,Lars K Poulsen,Graham Roberts,Peter Schmid-Grendelmeier,Chrysanthi Skevaki,Massimo Triggiani,Ronald vanRee,Thomas Werfel,Breda Flood,Susanna Palkonen,Roberta Savli,Pia Allegri,Isabella Annesi-Maesano,Francesco Annunziato,Dario Antolin-Amerigo,Christian Apfelbacher,Miguel Blanca,Ewa Bogacka,Patrizia Bonadonna,Matteo Bonini,Onur Boyman,Knut Brockow,Peter Burney,Jeroen Buters,Indre Butiene,Moises Calderon,Lars Olaf Cardell,Jean-Christoph Caubet,Sevcan Celenk,Ewa Cichocka-Jarosz,Cemal Cingi,Mariana Couto,Nicolette deJong,Stefano Del Giacco,Nikolaos Douladiris,Filippo Fassio,Jean-Luc Fauquert,Javier Fernandez,Montserrat Fernandez Rivas,Marta Ferrer,Carsten Flohr,James Gardner,Jon Genuneit,Philippe Gevaert,Anna Groblewska,Eckard Hamelmann,Hans Jürgen Hoffmann,Karin Hoffmann-Sommergruber,Lilit Hovhannisyan,Valérie Hox,Frode L Jahnsen,Ömer Kalayci,Ayse Füsun Kalpaklioglu,Jörg Kleine-Tebbe,George Konstantinou,Marcin Kurowski,Susanne Lau,Roger Lauener,Antti Lauerma,Kirsty Logan,Antoine Magnan,Joanna Makowska,Heidi Makrinioti,Paraskevi Mangina,Felicia Manole,Adriano Mari,Angel Mazon,Clare Mills,ErvinÇ Mingomataj,Bodo Niggemann,Gunnar Nilsson,Markus Ollert,Liam O'Mahony,Serena O'Neil,Gianni Pala,Alberto Papi,Gianni Passalacqua,Michael Perkin,Oliver Pfaar,Constantinos Pitsios,Santiago Quirce,Ulrike Raap,Monika Raulf-Heimsoth,Claudio Rhyner,Paula Robson-Ansley,Rodrigo Rodrigues Alves,Zeljka Roje,Carmen Rondon,Odilija Rudzeviciene,Franziska Ruëff,Maia Rukhadze,Gabriele Rumi,Cansin Sackesen,Alexandra F Santos,Annalisa Santucci,Christian Scharf,Carsten Schmidt-Weber,Benno Schnyder,Jürgen Schwarze,Gianenrico Senna,Svetlana Sergejeva,Sven Seys,Andrea Siracusa,Isabel Skypala,Milena Sokolowska,Francois Spertini,Radoslaw Spiewak,Aline Sprikkelman,Gunter Sturm,Ines Swoboda,Ingrid Terreehorst,Elina Toskala,Claudia Traidl-Hoffmann,Carina Venter,Berber Vlieg-Boerstra,Paul Whitacker,Margitta Worm,Paraskevi Xepapadaki,Cezmi A Akdis,Jan Monchy,Peter Schmid‐Grendelmeier,Ronald Ree,Isabella Annesi‐Maesano,Dario Antolin‐Amerigo,Jean‐Christoph Caubet,Ewa Cichocka‐Jarosz,Nicolette Jong,Jean‐Luc Fauquert,Karin Hoffmann‐Sommergruber,Jörg Kleine‐Tebbe,Monika Raulf‐Heimsoth,Paula Robson‐Ansley,Carsten Schmidt‐Weber,Claudia Traidl‐Hoffmann,Berber Vlieg‐Boerstra

DOI: https://doi.org/10.1186/2045-7022-2-21

2012-01-01

Clinical and Translational Allergy

Abstract:In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.

allergy
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Moises A Calderon,Pascal Demoly,Roy Gerth van Wijk,Jean Bousquet,Aziz Sheikh,Anthony Frew,Glenis Scadding,Claus Bachert,Hans J Malling,Rudolph Valenta,Beatrice Bilo,Antonio Nieto,Cezmi Akdis,Jocelyne Just,Carmen Vidal,Eva M Varga,Emilio Alvarez-Cuesta,Barbara Bohle,Albrecht Bufe,Walter G Canonica,Victoria Cardona,Ronald Dahl,Alain Didier,Stephen R Durham,Peter Eng,Montserrat Fernandez-Rivas,Lars Jacobsen,Marek Jutel,Jörg Kleine-Tebbe,Ludger Klimek,Jan Lötvall,Carmen Moreno,Ralph Mosges,Antonella Muraro,Bodo Niggemann,Giovanni Pajno,Giovanni Passalacqua,Oliver Pfaar,Sabina Rak,Gianenrico Senna,Gabriela Senti,Erkka Valovirta,Marianne van Hage,Johannes C Virchow,Ulrich Wahn,Nikolaos Papadopoulos

DOI: https://doi.org/10.1186/2045-7022-2-20

2012-10-30

Abstract:Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals' quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.
EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

P W Hellings,S Lau,G K Scadding,L Bjermer,V Backer,A M Chaker,D M Conti,E De Corso,Z Diamant,R Djukanovic,W Fokkens,P Gevaert,C L Gray,J K Han,L G Heaney,H J Hoffmann,M Jesenak,P Johansen,M S Kumaran,M McDonald,E Melén,J Mullol,S Reitsma,D Ryan,G Scadding,P Schmid-Grendelmeier,T Teeling,M Odemyr,U Wahn

DOI: https://doi.org/10.3389/falgy.2023.1236977

2023-07-27

Abstract:In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.
Omics technologies in allergy and asthma research: An EAACI position paper

Urszula Radzikowska,Katja Baerenfaller,José Antonio Cornejo-Garcia,Cagatay Karaaslan,Elena Barletta,Basak Ezgi Sarac,Damir Zhakparov,Alma Villaseñor,Ibon Eguiluz-Gracia,Cristobalina Mayorga,Milena Sokolowska,Coral Barbas,Domingo Barber,Markus Ollert,Tomas Chivato,Ioana Agache,Maria M Escribese

DOI: https://doi.org/10.1111/all.15412

IF: 12.4

Allergy

Abstract:Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. The increasing availability of high-throughput omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics allows studying biochemical systems and pathophysiological processes underlying allergic responses. Additionally, omics techniques present clinical applicability by functional identification and validation of biomarkers. Therefore, finding molecules or patterns characteristic for distinct immune-inflammatory endotypes, can subsequently influence its development, progression, and treatment. There is a great potential to further increase the effectiveness of single omics approaches by integrating them with other omics, and nonomics data. Systems biology aims to simultaneously and longitudinally understand multiple layers of a complex and multifactorial disease, such as allergy, or asthma by integrating several, separated data sets and generating a complete molecular profile of the condition. With the use of sophisticated biostatistics and machine learning techniques, these approaches provide in-depth insight into individual biological systems and will allow efficient and customized healthcare approaches, called precision medicine. In this EAACI Position Paper, the Task Force "Omics technologies in allergic research" broadly reviewed current advances and applicability of omics techniques in allergic diseases and asthma research, with a focus on methodology and data analysis, aiming to provide researchers (basic and clinical) with a desk reference in the field. The potential of omics strategies in understanding disease pathophysiology and key tools to reach unmet needs in allergy precision medicine, such as successful patients' stratification, accurate disease prognosis, and prediction of treatment efficacy and successful prevention measures are highlighted.
The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction

F. Distler,J. Radtke,D. Bonekamp,C. Kesch,H. Schlemmer,K. Wieczorek,M. Kirchner,S. Pahernik,M. Hohenfellner,B. Hadaschik

DOI: https://doi.org/10.1016/j.juro.2017.03.130

2017-09-01

Abstract:
EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Ioana Agache,Dario Antolin‐Amerigo,Frederic Blay,Cristina Boccabella,Cristiano Caruso,Pascal Chanez,Mariana Couto,Ronina Covar,Serge Doan,Jean‐Luc Fauquert,Gail Gauvreau,Alina Gherasim,Ludger Klimek,Catherine Lemiere,Parameswaran Nair,Iñigo Ojanguren,David Peden,Luis Perez‐de‐Llano,Oliver Pfaar,Carmen Rondon,Maia Rukhazde,Joaquin Sastre,Johannes Schulze,Diana Silva,Susan Tarlo,Sanna Toppila‐Salmi,Jolanta Walusiak‐Skorupa,Stefan Zielen,Ibon Eguiluz‐Gracia

DOI: https://doi.org/10.1111/all.15203

IF: 12.4

2022-01-20

Allergy

Abstract:Allergic asthma (AA) is a common asthma phenotype, and its diagnosis requires both the demonstration of IgE-sensitization to aeroallergens and the causative role of this sensitization as a major driver of asthma symptoms. Therefore, a bronchial allergen challenge (BAC) would be occasionally required to identify AA patients among atopic asthmatics. Nevertheless, BAC is usually considered a research tool only, with existing protocols being tailored to mild asthmatics and research needs (eg long washout period for inhaled corticosteroids). Consequently, existing BAC protocols are not designed to be performed in moderate-to-severe asthmatics or in clinical practice. The correct diagnosis of AA might help select patients for immunomodulatory therapies. Allergen sublingual immunotherapy is now registered and recommended for controlled or partially controlled patients with house dust mite-driven AA and with FEV1 ≥ 70%. Allergen avoidance is costly and difficult to implement for the management of AA, so the proper selection of patients is also beneficial. In this position paper, the EAACI Task Force proposes a methodology for clinical BAC that would need to be validated in future studies. The clinical implementation of BAC could ultimately translate into a better phenotyping of asthmatics in real life, and into a more accurate selection of patients for long-term and costly management pathways.

immunology,allergy
Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Jean Bousquet,Mohamed H Shamji,Josep M Anto,Holger J Schünemann,G Walter Canonica,Marek Jutel,Stefano Del Giacco,Torsten Zuberbier,Oliver Pfaar,Joao A Fonseca,Bernardo Sousa-Pinto,Ludger Klimek,Wienczyslawa Czarlewski,Anna Bedbrook,Rita Amaral,Ignacio J Ansotegui,Sinthia Bosnic-Anticevich,Fulvio Braido,Claudia Chaves Loureiro,Bilun Gemicioglu,Tari Haahtela,Marek Kulus,Piotr Kuna,Maciej Kupczyk,Paolo M Matricardi,Frederico S Regateiro,Boleslaw Samolinski,Mikhail Sofiev,Sanna Toppila-Salmi,Arunas Valiulis,Maria Teresa Ventura,Cristina Barbara,Karl C Bergmann,Michael Bewick,Hubert Blain,Matteo Bonini,Louis-Philippe Boulet,Rodolphe Bourret,Guy Brusselle,Luisa Brussino,Roland Buhl,Victoria Cardona,Thomas Casale,Lorenzo Cecchi,Denis Charpin,Ivan Cherrez-Ojeda,Derek K Chu,Cemal Cingi,Elisio M Costa,Alvaro A Cruz,Philippe Devillier,Stephanie Dramburg,Wytske J Fokkens,Maia Gotua,Enrico Heffler,Zhanat Ispayeva,Juan Carlos Ivancevich,Guy Joos,Igor Kaidashev,Helga Kraxner,Violeta Kvedariene,Désirée E Larenas-Linnemann,Daniel Laune,Olga Lourenço,Renaud Louis,Mika Makela,Michael Makris,Marcus Maurer,Erik Melén,Yann Micheli,Mario Morais-Almeida,Joaquim Mullol,Marek Niedoszytko,Robyn O'Hehir,Yoshitaka Okamoto,Heidi Olze,Nikolaos G Papadopoulos,Alberto Papi,Vincenzo Patella,Benoit Pétré,Nhân Pham-Thi,Francesca Puggioni,Santiago Quirce,Nicolas Roche,Philip W Rouadi,Ana Sá-Sousa,Hironori Sagara,Joaquin Sastre,Nicola Scichilone,Aziz Sheikh,Milan Sova,Charlotte Suppli Ulrik,Luis Taborda-Barata,Ana Todo-Bom,Maria J Torres,Ioanna Tsiligianni,Omar S Usmani,Erkka Valovirta,Tuula Vasankari,Rafael José Vieira,Dana Wallace,Susan Waserman,Mihaela Zidarn,Arzu Yorgancioglu,Luo Zhang,Tomas Chivato,Markus Ollert

DOI: https://doi.org/10.1111/all.15740

IF: 12.4

Allergy

Abstract:Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Heimo Breiteneder,Zuzana Diamant,Thomas Eiwegger,Kari Nadeau,Oliver Pfaar,De Yun Wang,Luo Zhang,Wytske J. Fokkens,Claudia Traidl‐Hoffmann,Robyn E. O’Hehir,Liam O’Mahony,Maria J. Torres,Cezmi A. Akdis

DOI: https://doi.org/10.1111/all.13851

IF: 12.4

2019-06-04

Allergy

Abstract:The specialties of allergy and clinical immunology have entered the era of precision medicine with the stratification of diseases into distinct disease subsets, specific diagnoses and targeted treatment options, including biologicals and small molecules. This article reviews recent developments in research and patient care and future trends in the discipline. The section on basic mechanisms of allergic diseases summarizes the current status and defines research needs in structural biology, type 2 inflammation, immune tolerance, neuroimmune mechanisms, role of the microbiome and diet, environmental factors, and respiratory viral infections. In the diagnostic challenges section, clinical trials, precision medicine and immune monitoring of allergic diseases, asthma, allergic and non‐allergic rhinitis and new approaches to the diagnosis and treatment of drug hypersensitivity reactions are discussed in further detail. In the third section, unmet needs and future research areas for the treatment of allergic diseases are highlighted with topics on food allergy, biologics, small molecules, and novel therapeutic concepts in allergen‐specific immunotherapy for airway disease Unknowns and future research needs are discussed at the end of each subsection.

immunology,allergy
Toward personalization of asthma treatment according to trigger factors.

Katarzyna Niespodziana,Kristina Borochova,Petra Pazderova,Thomas Schlederer,Natalia Astafyeva,Tatiana Baranovskaya,Mohamed-Ridha Barbouche,Evgeny Beltyukov,Angelika Berger,Elena Borzova,Jean Bousquet,Roxana S Bumbacea,Snezhana Bychkovskaya,Luis Caraballo,Kian Fan Chung,Adnan Custovic,Guillermo Docena,Thomas Eiwegger,Irina Evsegneeva,Alexander Emelyanov,Peter Errhalt,Rustem Fassakhov,Rezeda Fayzullina,Elena Fedenko,Daria Fomina,Zhongshan Gao,Pedro Giavina-Bianchi,Maia Gotua,Susanne Greber-Platzer,Gunilla Hedlin,Natalia Ilina,Zhanat Ispayeva,Marco Idzko,Sebastian L Johnston,Ömer Kalayci,Alexander Karaulov,Antonina Karsonova,Musa Khaitov,Elena Kovzel,Marek L Kowalski,Dmitry Kudlay,Michael Levin,Svetlana Makarova,Paolo Maria Matricardi,Kari C Nadeau,Leyla Namazova-Baranova,Olga Naumova,Oleksandr Nazarenko,Paul M O'Byrne,Faith Osier,Alexander N Pampura,Carmen Panaitescu,Nikolaos G Papadopoulos,Hae-Sim Park,Ruby Pawankar,Wolfgang Pohl,Harald Renz,Ksenja Riabova,Vanitha Sampath,Bülent E Sekerel,Elopy Sibanda,Valérie Siroux,Ludmila P Sizyakina,Jin-Lyu Sun,Zsolt Szepfalusi,Tetiana Umanets,Hugo P S Van Bever,Marianne van Hage,Margarita Vasileva,Erika von Mutius,Jiu-Yao Wang,Gary W K Wong,Sergii Zaikov,Mihaela Zidarn,Rudolf Valenta

DOI: https://doi.org/10.1016/j.jaci.2020.02.001

2020-01-01

Abstract:Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma.
Pharyngoesophageal barotrauma in children: a report of six cases.

A. Conlan,A. Wessels,C. Hammond,P. Beale,G. Katz

DOI: https://doi.org/10.1016/S0022-5223(19)38334-5

IF: 6.439

1984-09-01

Journal of Thoracic and Cardiovascular Surgery

Abstract:
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

J Jean Bousquet,Holger J Schünemann,Alkis Togias,Marina Erhola,Peter W Hellings,Torsten Zuberbier,Ioana Agache,Ignacio J Ansotegui,Josep M Anto,Claus Bachert,Sven Becker,Martin Bedolla-Barajas,Michael Bewick,Sinthia Bosnic-Anticevich,Isabelle Bosse,Louis P Boulet,Jean Marc Bourrez,Guy Brusselle,Niels Chavannes,Elisio Costa,Alvaro A Cruz,Wienczyslawa Czarlewski,Wytske J Fokkens,Joao A Fonseca,Mina Gaga,Tari Haahtela,Maddalena Illario,Ludger Klimek,Piotr Kuna,Violeta Kvedariene,L T T Le,Desiree Larenas-Linnemann,Daniel Laune,Olga M Lourenço,Enrica Menditto,Joaquin Mullol,Yashitaka Okamoto,Nikos Papadopoulos,Nhân Pham-Thi,Robert Picard,Hilary Pinnock,Nicolas Roche,Regina E Roller-Wirnsberger,Christine Rolland,Boleslaw Samolinski,Aziz Sheikh,Sanna Toppila-Salmi,Ioanna Tsiligianni,Arunas Valiulis,Erkka Valovirta,Tuula Vasankari,Maria-Teresa Ventura,Samantha Walker,Sian Williams,Cezmi A Akdis,Isabella Annesi-Maesano,Sylvie Arnavielhe,Xavier Basagana,Eric Bateman,Anna Bedbrook,K S Bennoor,Samuel Benveniste,Karl C Bergmann,Slawomir Bialek,Nils Billo,Carsten Bindslev-Jensen,Leif Bjermer,Hubert Blain,Mateo Bonini,Philippe Bonniaud,Jacques Bouchard,Vitalis Briedis,Christofer E Brightling,Jan Brozek,Roland Buhl,Roland Buonaiuto,Giorgo W Canonica,Victoria Cardona,Ana M Carriazo,Warner Carr,Christine Cartier,Thomas Casale,Lorenzo Cecchi,Alfonso M Cepeda Sarabia,Eka Chkhartishvili,Derek K Chu,Cemal Cingi,Elaine Colgan,Jaime Correia de Sousa,Anne Lise Courbis,Adnan Custovic,Biljana Cvetkosvki,Gennaro D'Amato,Jane da Silva,Carina Dantas,Dejand Dokic,Yves Dauvilliers,Antoni Dedeu,Giulia De Feo,Philippe Devillier,Stefania Di Capua,Marc Dykewickz,Ruta Dubakiene,Motohiro Ebisawa,Yaya El-Gamal,Esben Eller,Regina Emuzyte,John Farrell,Antjie Fink-Wagner,Alessandro Fiocchi,Jean F Fontaine,Bilun Gemicioğlu,Peter Schmid-Grendelmeir,Amiran Gamkrelidze,Judith Garcia-Aymerich,Maximiliano Gomez,Sandra González Diaz,Maia Gotua,Nick A Guldemond,Maria-Antonieta Guzmán,Jawad Hajjam,John O'B Hourihane,Marc Humbert,Guido Iaccarino,Despo Ierodiakonou,Juan C Ivancevich,Guy Joos,Ki-Suck Jung,Marek Jutel,Igor Kaidashev,Omer Kalayci,Przemyslaw Kardas,Thomas Keil,Mussa Khaitov,Nikolai Khaltaev,Jorg Kleine-Tebbe,Marek L Kowalski,Vicky Kritikos,Inger Kull,Lisa Leonardini,Philip Lieberman,Brian Lipworth,Karin C Lodrup Carlsen,Claudia C Loureiro,Renaud Louis,Alpana Mair,Gert Marien,Bassam Mahboub,Joao Malva,Patrick Manning,Esteban De Manuel Keenoy,Gailen D Marshall,Mohamed R Masjedi,Jorge F Maspero,Eve Mathieu-Dupas,Poalo M Matricardi,Eric Melén,Elisabete Melo-Gomes,Eli O Meltzer,Jacques Mercier,Neven Miculinic,Florin Mihaltan,Branislava Milenkovic,Giuliana Moda,Maria-Dolores Mogica-Martinez,Yousser Mohammad,Steve Montefort,Ricardo Monti,Mario Morais-Almeida,Ralf Mösges,Lars Münter,Antonella Muraro,Ruth Murray,Robert Naclerio,Luigi Napoli,Leila Namazova-Baranova,Hugo Neffen,Kristoff Nekam,Angelo Neou,Enrico Novellino,Dieudonné Nyembue,Robin O'Hehir,Ken Ohta,Kimi Okubo,Gabrielle Onorato,Solange Ouedraogo,Isabella Pali-Schöll,Susanna Palkonen,Peter Panzner,Hae-Sim Park,Jean-Louis Pépin,Ana-Maria Pereira,Oliver Pfaar,Ema Paulino,Jim Phillips,Davor Plavec,Ted A Popov,Fabienne Portejoie,David Price,Emmanuel P Prokopakis,Benoit Pugin,Filip Raciborski,Rojin Rajabian-Söderlund,Sietze Reitsma,Xavier Rodo,Antonino Romano,Nelson Rosario,Menahenm Rottem,Dermot Ryan,Johanna Salimäki,Mario M Sanchez-Borges,Juan-Carlos Sisul,Dirceu Solé,David Somekh,Talant Sooronbaev,Milan Sova,Otto Spranger,Cristina Stellato,Rafael Stelmach,Charlotte Suppli Ulrik,Michel Thibaudon,Teresa To,Ana Todo-Bom,Peter V Tomazic,Antonio A Valero,Rudolph Valenta,Marylin Valentin-Rostan,Rianne van der Kleij,Olivier Vandenplas,Giorgio Vezzani,Frédéric Viart,Giovanni Viegi,Dana Wallace,Martin Wagenmann,De Y Wang,Susan Waserman,Magnus Wickman,Dennis M Williams,Gary Wong,Piotr Wroczynski,Panayiotis K Yiallouros,Arzu Yorgancioglu,Osman M Yusuf,Heahter J Zar,Stéphane Zeng,Mario Zernotti,Luo Zhang,Nan S Zhong,Mihaela Zidarn,ARIA Study Group,MASK Study Group

DOI: https://doi.org/10.1186/s13601-019-0279-2

2019-09-09

Abstract:Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

Sinthia Bosnic-Anticevich,Elisio Costa,Enrica Menditto,Olga Lourenço,Ettore Novellino,Slawomir Bialek,Vitalis Briedis,Roland Buonaiuto,Henry Chrystyn,Biljana Cvetkovski,Stefania Di Capua,Vicky Kritikos,Alpana Mair,Valentina Orlando,Ema Paulino,Johanna Salimäki,Rojin Söderlund,Rachel Tan,Dennis M Williams,Piotr Wroczynski,Ioana Agache,Ignacio J Ansotegui,Josep M Anto,Anna Bedbrook,Claus Bachert,Mike Bewick,Carsten Bindslev-Jensen,Jan L Brozek,Giorgio Walter Canonica,Victoria Cardona,Warner Carr,Thomas B Casale,Niels H Chavannes,Jaime Correia de Sousa,Alvaro A Cruz,Wienczyslawa Czarlewski,Giuseppe De Carlo,Pascal Demoly,Philippe Devillier,Mark S Dykewicz,Mina Gaga,Yehia El-Gamal,João Fonseca,Wytske J Fokkens,Maria Antonieta Guzmán,Tari Haahtela,Peter W Hellings,Maddalena Illario,Juan Carlos Ivancevich,Jocelyne Just,Igor Kaidashev,Musa Khaitov,Nikolai Khaltaev,Thomas Keil,Ludger Klimek,Marek L Kowalski,Piotr Kuna,Violeta Kvedariene,Désirée E Larenas-Linnemann,Daniel Laune,Lan T T Le,Karin C Lodrup Carlsen,Bassam Mahboub,Dieter Maier,Joao Malva,Patrick J Manning,Mário Morais-Almeida,Ralph Mösges,Joaquim Mullol,Lars Münter,Ruth Murray,Robert Naclerio,Leyla Namazova-Baranova,Kristof Nekam,Tshipukane Dieudonné Nyembue,Kimi Okubo,Robyn E O'Hehir,Ken Ohta,Yoshitaka Okamoto,Gabrielle L Onorato,Susanna Palkonen,Petr Panzner,Nikolaos G Papadopoulos,Hae-Sim Park,Ruby Pawankar,Oliver Pfaar,Jim Phillips,Davor Plavec,Todor A Popov,Paul C Potter,Emmanuel P Prokopakis,Regina E Roller-Wirnsberger,Menachem Rottem,Dermot Ryan,Bolesław Samolinski,Mario Sanchez-Borges,Holger J Schunemann,Aziz Sheikh,Juan Carlos Sisul,David Somekh,Cristiana Stellato,Teresa To,Ana Maria Todo-Bom,Peter Valentin Tomazic,Sanna Toppila-Salmi,Antonio Valero,Arunas Valiulis,Errka Valovirta,Maria Teresa Ventura,Martin Wagenmann,Dana Wallace,Susan Waserman,Magnus Wickman,Panayiotis K Yiallouros,Arzu Yorgancioglu,Osman M Yusuf,Heather J Zar,Mario E Zernotti,Luo Zhang,Mihaela Zidarn,Torsten Zuberbier,Jean Bousquet

DOI: https://doi.org/10.1111/all.13701

IF: 12.4

Allergy

Abstract:Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care.
Expanding Options in House Dust Mite Allergy Immunotherapy: Optimising Individual Patient Outcomes

Moisés Calderón,Thomas Casale,Petra Zieglmayer,Philippe Gevaert,Pascal Demoly

DOI: https://doi.org/10.33590/emjallergyimmunol/10314549

2019-07-18

EMJ Allergy & Immunology

Abstract:Prof Calderón opened the symposium by noting its overall aim: to improve outcomes in patients with allergic diseases. Currently, patients can wait an average of 8.5 years to see an allergy specialist and this places a significant burden on individuals. Traditional therapeutic management of patients with allergies is suboptimal, and while appropriate use of allergen immunotherapy (AIT) maximises its impact, treatment guidelines are complex. Prof Zieglmayer explained that house dust mite (HDM) allergy is a global problem. Allergic rhinitis (AR) drives asthma, with the highest risk in children. Symptoms associated with AR and allergic rhino-conjunctivitis can be different in children compared with adults and adolescents. A holistic approach is needed that treats not only the classic symptoms of AR, but also the accompanying physical and mental impairment. It is critical that clinicians gain a greater understanding of the unique burden of AR in order to better treat their patients. Prof Gevaert emphasised that precision medicine is key to optimising patient outcomes and that advances have been made in this area, particularly with artificial intelligence. For children, the ultimate aim is to achieve an early diagnosis and use precision medicine for early prevention and treatment with AIT. For adults, better help is required with uncontrolled allergic disease. Precision medicine will make use of all available data to help select patients who are most likely to benefit from AIT. Prof Demoly summarised data from a Phase III randomised, double-blind, placebo-controlled clinical trial that demonstrated the efficacy and safety of a 300IR HDM sublingual immunotherapy (SLIT) tablet in adults and adolescents with HDM-associated AR. Concluding, Prof Casale reiterated that AIT is a crucial tool in the therapeutic armamentarium against HDM allergy and should be used for early prevention and early treatment, without delay.
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

J. Bousquet,,A. Bedbrook,W. Czarlewski,G. L. Onorato,S. Arnavielhe,D. Laune,E. Mathieu-Dupas,J. Fonseca,E. Costa,O. Lourenço,M. Morais-Almeida,A. Todo-Bom,M. Illario,E. Menditto,G. W. Canonica,L. Cecchi,R. Monti,L. Napoli,M. T. Ventura,G. De Feo,W. J. Fokkens,N. H. Chavannes,S. Reitsma,A. A. Cruz,J. da Silva,F. S. Serpa,D. Larenas-Linnemann,J. M. Fuentes Perez,Y. R. Huerta-Villalobos,D. Rivero-Yeverino,E. Rodriguez-Zagal,A. Valiulis,R. Dubakiene,R. Emuzyte,V. Kvedariene,I. Annesi-Maesano,H. Blain,P. Bonniaud,I. Bosse,Y. Dauvilliers,P. Devillier,J. F. Fontaine,J. L. Pépin,N. Pham-Thi,F. Portejoie,R. Picard,N. Roche,C. Rolland,P. Schmidt-Grendelmeier,P. Kuna,B. Samolinski,J. M. Anto,V. Cardona,J. Mullol,H. Pinnock,D. Ryan,A. Sheikh,S. Walker,S. Williams,S. Becker,L. Klimek,O. Pfaar,K. C. Bergmann,R. Mösges,T. Zuberbier,R. E. Roller-Wirnsberger,P. V. Tomazic,T. Haahtela,J. Salimäki,S. Toppila-Salmi,E. Valovirta,T. Vasankari,B. Gemicioğlu,A. Yorgancioglu,N. G. Papadopoulos,E. P. Prokopakis,I. G. Tsiligianni,S. Bosnic-Anticevich,R. O’Hehir,J. C. Ivancevich,H. Neffen,M. E. Zernotti,I. Kull,E. Melén,M. Wickman,C. Bachert,P. W. Hellings,G. Brusselle,S. Palkonen,C. Bindslev-Jensen,E. Eller,S. Waserman,L. P. Boulet,J. Bouchard,D. K. Chu,H. J. Schünemann,M. Sova,G. De Vries,M. van Eerd,I. Agache,I. J. Ansotegui,M. Bewick,T. Casale,M. Dykewick,M. Ebisawa,R. Murray,R. Naclerio,Y. Okamoto,D. V. Wallace,

DOI: https://doi.org/10.1186/s13601-019-0252-0

2019-03-11

Clinical and Translational Allergy

Abstract:AIMS: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.METHODS: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.STAKEHOLDERS: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors.RESULTS: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.EU GRANTS 2018: MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour).LESSONS LEARNT: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

allergy
Goal adjustment capacities, coping, and subjective well-being: the sample case of caregiving for a family member with mental illness.

C. Wrosch,E. Amir,G. Miller

DOI: https://doi.org/10.1037/a0022873

IF: 8.46

2011-05-01

Journal of Personality and Social Psychology

Abstract:This study examined the associations between goal adjustment capacities, coping, and indicators of subjective well-being in 2 waves of data from individuals who provide care for a family member with mental illness. We hypothesized that goal adjustment capacities would predict higher levels of subjective well-being by facilitating coping with caregiving stress. Results showed that goal disengagement was associated with effective care-specific coping (e.g., less self-blame and substance use). Goal reengagement was also associated with effective care-specific coping (e.g., positive reframing), but at the same time it predicted the use of less effective strategies (e.g., venting and self-distraction). Moreover, goal disengagement predicted lower levels of caregiver burden and depressive symptoms and buffered the longitudinal effect of caregiver burden on increases in depressive symptoms. Goal reengagement, by contrast, predicted higher levels of caregiver burden and purpose in life and buffered the cross-sectional association between caregiver burden and depressive symptoms. Finally, effective (and less useful) care-specific coping statistically explained the adaptive (and maladaptive) effects of goal adjustment capacities on participants' well-being.
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

J Bousquet,E Melén,T Haahtela,G H Koppelman,A Togias,R Valenta,C A Akdis,W Czarlewski,M Rothenberg,A Valiulis,M Wickman,M Akdis,D Aguilar,A Bedbrook,C Bindslev-Jensen,S Bosnic-Anticevich,L P Boulet,C E Brightling,L Brussino,E Burte,M Bustamante,G W Canonica,L Cecchi,J C Celedon,C Chaves Loureiro,E Costa,A A Cruz,M Erhola,B Gemicioglu,W J Fokkens,J Garcia-Aymerich,S Guerra,J Heinrich,J C Ivancevich,T Keil,L Klimek,P Kuna,M Kupczyk,V Kvedariene,D E Larenas-Linnemann,N Lemonnier,K C Lodrup Carlsen,R Louis,M Makela,M Makris,M Maurer,I Momas,M Morais-Almeida,J Mullol,R N Naclerio,K Nadeau,R Nadif,M Niedoszytko,Y Okamoto,M Ollert,N G Papadopoulos,G Passalacqua,V Patella,R Pawankar,N Pham-Thi,O Pfaar,F S Regateiro,J Ring,P W Rouadi,B Samolinski,J Sastre,M Savouré,N Scichilone,M H Shamji,A Sheikh,V Siroux,B Sousa-Pinto,M Standl,J Sunyer,L Taborda-Barata,S Toppila-Salmi,M J Torres,I Tsiligianni,E Valovirta,O Vandenplas,M T Ventura,S Weiss,A Yorgancioglu,L Zhang,A H Abdul Latiff,W Aberer,I Agache,M Al-Ahmad,I Alobid,I J Ansotegui,S H Arshad,E Asayag,C Barbara,A Baharudin,L Battur,K S Bennoor,E C Berghea,K C Bergmann,D Bernstein,M Bewick,H Blain,M Bonini,F Braido,R Buhl,R S Bumbacea,A Bush,M Calderon,M Calvo-Gil,P Camargos,L Caraballo,V Cardona,W Carr,P Carreiro-Martins,T Casale,A M Cepeda Sarabia,R Chandrasekharan,D Charpin,Y Z Chen,I Cherrez-Ojeda,T Chivato,E Chkhartishvili,G Christoff,D K Chu,C Cingi,J Correia de Sousa,C Corrigan,A Custovic,G D'Amato,S Del Giacco,F De Blay,P Devillier,A Didier,M do Ceu Teixeira,D Dokic,H Douagui,M Doulaptsi,S Durham,M Dykewicz,T Eiwegger,Z A El-Sayed,R Emuzyte,A Fiocchi,N Fyhrquist,R M Gomez,M Gotua,M A Guzman,J Hagemann,S Hamamah,S Halken,D M G Halpin,M Hofmann,E Hossny,M Hrubiško,C Irani,Z Ispayeva,E Jares,T Jartti,E Jassem,K Julge,J Just,M Jutel,I Kaidashev,O Kalayci,A F Kalyoncu,P Kardas,B Kirenga,H Kraxner,I Kull,M Kulus,S La Grutta,S Lau,L Le Tuyet Thi,M Levin,B Lipworth,O Lourenço,B Mahboub,E Martinez-Infante,P Matricardi,N Miculinic,N Migueres,F Mihaltan,Y Mohammad,M Moniuszko,S Montefort,H Neffen,K Nekam,E Nunes,D Nyembue Tshipukane,R O'Hehir,I Ogulur,K Ohta,K Okubo,S Ouedraogo,H Olze,I Pali-Schöll,O Palomares,K Palosuo,C Panaitescu,P Panzner,H S Park,C Pitsios,D Plavec,T A Popov,F Puggioni,S Quirce,M Recto,M S Repka-Ramirez,C Robalo Cordeiro,N Roche,M Rodriguez-Gonzalez,J Romantowski,N Rosario Filho,M Rottem,H Sagara,F S Serpa,Z Sayah,S Scheire,P Schmid-Grendelmeier,J C Sisul,D Sole,M Soto-Martinez,M Sova,A Sperl,O Spranger,R Stelmach,C Suppli Ulrik,M Thomas,T To,A Todo-Bom,P V Tomazic,M Urrutia-Pereira,M Valentin-Rostan,E Van Ganse,M van Hage,T Vasankari,P Vichyanond,G Viegi,D Wallace,D Y Wang,S Williams,M Worm,P Yiallouros,O Yusuf,F Zaitoun,M Zernotti,M Zidarn,J Zuberbier,J A Fonseca,T Zuberbier,J M Anto

DOI: https://doi.org/10.1111/all.15679

IF: 12.4

Allergy

Abstract:Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease," coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis." This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
Multidisciplinary Approaches to Allergies

Zhong-Shan Gao,Min Zheng,Luud J. W. J. Gilissen,Hua-Hao Shen,Lynn J. Frewer

DOI: https://doi.org/10.1007/978-3-642-31609-8

2012-01-01

Abstract:Effective strategies can now be developed in emerging economies to alleviate the large-scale allergy problems which are predicted. Such strategies may be initiated from the perspective of the potentially allergic individual and from the allergenic agents. Regarding symptom development and its alleviation, three levels of prevention can be applied. Primary prevention addresses symptom-free children at risk in particular. Secondary prevention focuses on sensitized individuals in their societal context. Symptom development can be prevented by avoidance of the offending allergens in the environment and food. Tertiary prevention includes medical treatment of the (chronic) symptoms. Since all major allergens are assumed to be known, high-throughput genomics and proteomics analyses can now be applied to diagnose a novel food for the presence, the molecular composition and the expressed amount of one or more of these allergens.
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy

D. Ryan,R. Gerth van Wijk,E. Angier,M. Kristiansen,H. Zaman,A. Sheikh,V. Cardona,C. Vidal,A. Warner,I. Agache,S. Arasi,M. Fernandez‐Rivas,S. Halken,M. Jutel,S. Lau,G. Pajno,O. Pfaar,G. Roberts,G. Sturm,E. M. Varga,R. Van Ree,A. Muraro,M. Fernandez-Rivas

DOI: https://doi.org/10.1111/all.13264

IF: 12.4

2017-12-12

Allergy

Abstract:PURPOSE: The European Academy of Allergy and Clinical Immunology (EAACI) has produced Guidelines on Allergen Immunotherapy (AIT). We sought to gauge the preparedness of primary care to participate in the delivery of AIT in Europe.METHODS: We undertook a mixed-methods, situational analysis. This involved a purposeful literature search and two surveys: one to primary care clinicians and the other to a wider group of stakeholders across Europe.RESULTS: The 10 papers identified all pointed out gaps or deficiencies in allergy care provision in primary care. The surveys also highlighted similar concerns, particularly in relation to concerns about lack of knowledge, skills, infrastructural weaknesses, reimbursement policies and communication with specialists as barriers to evidence-based care. Almost all countries (92%) reported the availability of AIT. In spite of that, only 28% and 44% of the countries reported the availability of guidelines for primary care physicians and specialists, respectively. Agreed pathways between specialists and primary care physicians were reported as existing in 32%-48% of countries. Reimbursement appeared to be an important barrier as AIT was only fully reimbursed in 32% of countries. Additionally, 44% of respondents considered accessibility to AIT and 36% stating patient costs were barriers.CONCLUSIONS: Successful working with primary care providers is essential to scaling-up AIT provision in Europe, but to achieve this, the identified barriers must be overcome. Development of primary care interpretation of guidelines to aid patient selection, establishment of disease management pathways and collaboration with specialist groups are required as a matter of urgency.

immunology,allergy
Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes

Josep M. Anto,Jean Bousquet,Mubeccel Akdis,Charles Auffray,Thomas Keil,Isabelle Momas,Dirkje S. Postma,Rudolf Valenta,Magnus Wickman,Anne Cambon-Thomsen,Tari Haahtela,Bart N. Lambrecht,Karin C. Lodrup Carlsen,Gerard H. Koppelman,Jordi Sunyer,Torsten Zuberbier,Isabelle Annesi-Maesano,Albert Arno,Carsten Bindslev-Jensen,Giuseppe De Carlo,Francesco Forastiere,Joachim Heinrich,Marek L. Kowalski,Dieter Maier,Erik Melén,Henriette A. Smit,Marie Standl,John Wright,Anna Asarnoj,Marta Benet,Natalia Ballardini,Judith Garcia-Aymerich,Ulrike Gehring,Stefano Guerra,Cynthia Hohmann,Inger Kull,Christian Lupinek,Mariona Pinart,Ingebjorg Skrindo,Marit Westman,Delphine Smagghe,Cezmi Akdis,Niklas Andersson,Claus Bachert,Stephane Ballereau,Ferran Ballester,Xavier Basagana,Anna Bedbrook,Anna Bergstrom,Andrea von Berg,Bert Brunekreef,Emilie Burte,Kai-Hakon Carlsen,Leda Chatzi,Jonathan M. Coquet,Mirela Curin,Pascal Demoly,Esben Eller,Maria Pia Fantini,Leena von Hertzen,Vergard Hovland,Benedicte Jacquemin,Jocelyne Just,Theresa Keller,Renata Kiss,Manolis Kogevinas,Sibylle Koletzko,Susanne Lau,Irina Lehmann,Nicolas Lemonnier,Mika Mäkelä,Jordi Mestres,Peter Mowinckel,Rachel Nadif,Martijn C. Nawijn,Johan Pellet,Isabelle Pin,Daniela Porta,Fanny Rancière,Emmanuelle Rial-Sebbag,Yvan Saeys,Martijn J. Schuijs,Valerie Siroux,Christina G. Tischer,Mathies Torrent,Raphaelle Varraso,Kalus Wenzel,Cheng-Jian Xu

DOI: https://doi.org/10.1016/j.jaci.2016.12.940

IF: 14.29

2017-02-01

Journal of Allergy and Clinical Immunology

Abstract:Asthma, rhinitis, and eczema are complex diseases with multiple genetic and environmental factors interlinked through IgE-associated and non-IgE-associated mechanisms. Mechanisms of the Development of ALLergy (MeDALL; EU FP7-CP-IP; project no: 261357; 2010-2015) studied the complex links of allergic diseases at the clinical and mechanistic levels by linking epidemiologic, clinical, and mechanistic research, including in vivo and in vitro models. MeDALL integrated 14 European birth cohorts, including 44,010 participants and 160 cohort follow-ups between pregnancy and age 20 years. Thirteen thousand children were prospectively followed after puberty by using a newly standardized MeDALL Core Questionnaire. A microarray developed for allergen molecules with increased IgE sensitivity was obtained for 3,292 children. Estimates of air pollution exposure from previous studies were available for 10,000 children. Omics data included those from historical genome-wide association studies (23,000 children) and DNA methylation (2,173), targeted multiplex biomarker (1,427), and transcriptomic (723) studies. Using classical epidemiology and machine-learning methods in 16,147 children aged 4 years and 11,080 children aged 8 years, MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of multimorbidity was attributable to IgE sensitization. MeDALL has proposed a new vision of multimorbidity independent of IgE sensitization, and has shown that monosensitization and polysensitization represent 2 distinct phenotypes. The translational component of MeDALL is shown by the identification of a novel allergic phenotype characterized by polysensitization and multimorbidity, which is associated with the frequency, persistence, and severity of allergic symptoms. The results of MeDALL will help integrate personalized, predictive, preventative, and participatory approaches in allergic diseases.

immunology,allergy
Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Heimo Breiteneder,Ya-Qi Peng,Ioana Agache,Zuzana Diamant,Thomas Eiwegger,Wytske J Fokkens,Claudia Traidl-Hoffmann,Kari Nadeau,Robyn E O'Hehir,Liam O'Mahony,Oliver Pfaar,Maria J Torres,De-Yun Wang,Luo Zhang,Cezmi A Akdis

DOI: https://doi.org/10.1111/all.14582

IF: 12.4

Allergy

Abstract:Modern health care requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping, and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions about the efficacy of the current management of allergic diseases require further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen immunotherapy with a special emphasis on specific IgE, the microbiome and the epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.

[Transthoracic intracavernous drug instillation].

Research needs in allergy: an EAACI position paper, in collaboration with EFA

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care

Omics technologies in allergy and asthma research: An EAACI position paper

The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction

EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Toward personalization of asthma treatment according to trigger factors.

Pharyngoesophageal barotrauma in children: a report of six cases.

Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

Expanding Options in House Dust Mite Allergy Immunotherapy: Optimising Individual Patient Outcomes

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

Goal adjustment capacities, coping, and subjective well-being: the sample case of caregiving for a family member with mental illness.

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

Multidisciplinary Approaches to Allergies

Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy

Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma